Skip to main content

Argenica partners with Oxford spinoff for stroke evaluation

15 hours ago

Bookmark

Save articles for future reference.

Perth-based Argenica Therapeutics has partnered with an Oxford University AI spinout to evaluate the effectiveness of its flagship ARG-007 stroke drug, finding previously hidden impacts.

X

To read our articles you will need to either login or subscribe.